All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Review Article - (2019) Volume 9, Issue 1

Effects and Therapeutic Use of TMS in Psychiatric Disorders: An Evidence-Based Review

Corresponding Author:
Dr. Isaac Túnez.
Dept. Biochemistry and Molecular Biology, Faculty of Medicine and Nursing, Av, Menendez Pidal s/n, Cordoba 14004, Cordoba, Spain



Recently we found that chronic immobilization stress (CIS) induced low levels of glutamate (Glu) and glutamine (Gln) and hypoactive glutamatergic signaling in the mouse prefrontal cortex (PFC), which was closely related with Glu-Gln cycle. Moreover, Gln-supplemented diet ameliorated CISinduced deleterious changes. In the present study, therefore, we investigated the effects of CIS and Gln supplementation on Glu-Gln cycle-related proteins to understand underlying mechanisms.


Using CIS-induced depression mouse model, we confirmed depressive behaviors caused by CIS and antidepressant property of Gln-supplementation with behavioral test and blood corticosterone assay. We examined expression of eleven proteins involving Glu-Gln cycle in the PFC.


CIS decreased glutamate transporter 1 (GLT1), sodium-coupled neutral amino acid transporter (SNAT) 3, SNAT5, and mature SNAT2, suggesting excitotoxicity in synaptic cleft and shortage of Glu and Gln in astrocytes and neurons. Gln-supplementation did not affect non-stressed group, but significantly increased SNAT1 and SNAT3, which are the major Gln transporter in neurons and astrocytes respectively, as well as the mature SNAT2, implicating increasing transportation of Gln into neurons.


As a result, we confirmed that CIS disturbed Glu-Gln cycle toward shortage of Glu and Gln levels in astrocytes and neurons, but Gln supplementation changed Glu-Gln cycle toward facilitating translocation of Gln into neurons for glutamatergic signaling. Moreover, these results also supported the antidepressant property of Gln.


Depression, Chronic stress, Glutamine, Glutamate-glutamine cycle, Glutamate transporter, Glutamine transporter, Prefrontal cortex


Transcranial Magnetic Stimulation (TMS) has been developed on the basis of a possible modulation of brain performance according to its electric environment. The physical process involved in TMS is simple and consists of the transformation of an electromagnetic field created by two coils connected to a generator into electrical energy when it passes through the skull and nervous tissue. This process, being safe [1], produces a transfer of ions across the cell membrane, finally leading to its depolarization or hyperpolarization. This results in stimulation or inhibition of the neuronal groups involved that are translated into clinical effects [2].

Psychiatric disorders have a histopathological basis that, in the vast majority of them, is not well characterized so that the symptoms are commonly defined as “pathophysiological disorder”. In this regard, psychiatric diseases seem to share alterations in the flow of brain neurotransmitters, especially serotonin, norepinephrine and dopamine; as well as other alterations in neurotropism, neuronal plasticity and biochemical processes related to cell dysfunction. Due to the ability demonstrated by TMS to act on all those processes [3], this fact might be at the basis of the therapeutic effects of TMS in psychiatric conditions such as schizophrenia, major depression and other mood disorders [4].

Nevertheless, to date, although high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) and low-frequency repetitive transcranial magnetic stimulation (LF-rTMS) remain as classic protocols; many other paradigms of TMS have been defined. Their different effects are closely related to the target of the stimulation, frequency used, and the number of stimuli or sessions, among others. Thus, with a constantly increasing number of publications on this area, it may be difficult to differentiate which protocols and in which clinical settings are really useful. According to this background, the aim of this review is to present the proven clinical therapeutic effects of TMS in psychiatric disorders, their possible underlying mechanisms and the determinants that may vary their outcomes, all according to the maximum level of evidence found to date.

To achieve this objective, an extensive review was conducted in using “transcranial magnetic stimulation” as a search term. No limitations were imposed. All references retrieved until October 2018 was carefully reviewed in looking for papers on therapeutic effects of TMS in psychiatric disorders. The inclusion criterion was the communication of a therapeutic effect. Studies regarding TMS as a non-therapeutic tool and those treating non-psychiatric conditions were excluded. Studies reporting experimental models were also considered. Initially, all types of publications were selected and, in a second step, only those with a maximum level of evidence found in each case were selected and included in the present manuscript (Figure 1). Evidence was established according to the document “Levels of Evidence 1” of the Oxford Centre for Evidence- Based Medicine (OCEBM), Levels of Evidence Working Group (March 2009).


Figure 1: Flow diagram showing yield of search and selection strategy.

In summary, this paper seeks to provide an evidence- based point of view of the therapeutic effects induced by current TMS-protocols, also briefly showing their possible biochemical pathways and clinical outcome determinants.


Schizophrenia is a common, serious and chronic psychiatric disorder with a globally lifetime prevalence of 0.5% to 1% [5]. The core alterations of this disorder are in relation to changes in the perception of reality. Its symptomatology has been classically divided into: positive (mainly hallucinations and delusions) and negative symptoms (emotional poverty, anhedonia, alogia and total apathy). The predominance of positive or negative symptoms allows the classification of this pathology into several clinical presentations that have their peculiarities in terms of evolution and treatment.

Pathophysiology of schizophrenia and determinants underlying the therapeutic effect of TMS

In recent years, the pathophysiology of schizophrenia has been extensively studied in order to find new therapies for this tragic disease. Toward this end, animal models play a key role [5]. Several studies have permitted one to demonstrate that the brain of patients with schizophrenia undergoes various pathophysiological alterations, which affect the flow of neurotransmitters such as dopamine, GABA, and glutamate; as well as the expression of genes and receptors related to them [6-8]. Moreover, these patients have also shown alterations in neurotrophic and neuroplastic processes [8,9], immune system and the secretion of pro-inflammatory cytokines [10,11], as well as oxidative balance [12,13], processes that can be modulated and counteracted by therapeutic TMS [3].

In this same line, according to some studies, the positive effects on symptomatology may be connected to both a reduction in hyperactivity, and, therefore, metabolism objectified in language regions involved in the emergence of auditory verbal hallucinations (AVH) [14], and a decreased cerebral blood flow in the primary auditory cortex [15], a finding that could be used to identify responders to therapy with TMS [16].

On the other hand, it has been suggested that the normalization of alpha and gamma oscillations related to the cognitive disorders in these patients may hold the key to the therapeutic outcomes of TMS in schizophrenia [17]. In this sense, it has been proven that Alpha and delta electroencephalography (EEG) normalization after treatment with Alpha-Delta-EEG-guided TMS (alpha TMS) over frontal and parietal areas may directly subserve the processes underlying clinical improvements in schizophrenia [18,19]. Similarly, rTMS therapy over the DLPFC may normalize excessive gamma oscillations and, ultimately, cognitive performance in schizophrenic patients [20].

On these bases, TMS might offer a therapeutic alternative to classic antipsychotic drugs, especially in those neuroleptic-resistant cases.

Effectiveness and medical evidence of classic rTMS-protocols in clinical settings

It has been about twenty years since the first references pointing to a possible therapeutic effect of TMS in schizophrenia were published [21,22]. Since then, numerous randomized clinical trials (RCTs) have been carried out to assess the effect of TMS on positive and negative symptoms. These results allowed the elaboration of several systematic reviews and meta-analyses that corroborate the potential use of this therapy, especially in those cases refractory to conventional treatment [23].

In this regard, a meta-analysis supporting a beneficial effect of repetitive transcranial magnetic stimulation (rTMS) on the AVH has been published by Slotema et al. [24]. This metaanalysis that included seventeen RCTs using LF-rTMS, evaluated AVH severity or psychosis severity as a primary goal. It concluded that the mean weighted effect size of rTMS when directed toward the left temporo-parietal cortex was 0.44 (95% CI, 0.19 - 0.68). However, this effect was no longer significant at one-month follow-up in any of the RCTs. According to some authors, this effect might be prolonged by up to six months using HF-rTMS (20 Hz) and functional magnetic resonance imaging (fMRI) to address the stimulation [25].

The results of the meta-analysis by Slotema et al. [24] are consistent in terms of therapeutic effectiveness on AVH with other similar works previously published [26,27]. Among them, it should be noted that, in 2007, Aleman et al. carried out a meta-analysis that included ten RCTs in which patients underwent LF-rTMS (1 Hz) to the left temporoparietal cortex [26]. After treatment calculation, the hallucination ratings gain obtained a significant mean weighted effect size for rTMS versus sham across the ten studies, involving 212 patients, d = 0.76 (95% CI, 0.36 - 1.17). This parameter increased to d = 0.88 when only nine studies using continuous stimulation were included. In addition, the heterogeneity of the analysis disappeared, thus proving the efficiency of LF-rTMS (1 Hz) on AVH [26]. This work found no beneficial effect on other positive symptoms as it was also concluded by another meta-analysis that included all prospective studies of the therapeutic application of LF-rTMS over the left temporoparietal cortex in refractory schizophrenia [28].

A study including twenty-one articles concerning 303 patients evaluated the magnitude of the placebo effect observed in controlled studies of rTMS treatment of AVH [29]). The mean weighted effect size of the placebo effect across these 21 studies was 0.29 (P < 0.001), but when the 21 articles were divided into parallel and crossover studies, only the placebo had a significant effect size in the 13 parallel studies (g=0.44, P < 10(-4)), but not in the 8 crossover ones (g=0.06, P=0.52).

In this latter study, Freitas et al. [28] also performed an analysis with pooled data from eight clinical trials that evaluated the effect of HFrTMS (10 Hz - 20 Hz) over the left dorsolateral prefrontal cortex (DLPFC) in the treatment of negative symptoms. In this regard, just a small beneficial effect was noted when including all studies. However, this effect disappeared when a potential placebo effect was considered, so that the usefulness and/or clinical relevance of HF-rTMS therapy in negative symptoms of patients with schizophrenia is doubtful and may be conditioned to the psychopathology severity and differences in results, measurements or TMS parameters [28].

A similarly slight effect on negative symptoms was found by another meta-analysis published a year later [30]. This study included nine RCTs (213 patients) that used HF-rTMS to the left DLPFC for the treatment of negative symptoms, and concluded that the overall mean weighted effect size for rTMS versus sham was statistically significant, d=0.43 (95% CI, 0.05 - 0.80) [30]. It should be noted that this mild effect improved when analyzed by subgroups. Therefore, this result rose when only studies with HF-rTMS (10 Hz) or a duration of treatment ≥ 3 weeks were included, d=0.63 (95% CI, 0.11 - 1.15) and d=0.58 (95% CI, 0.19 - 0.97), respectively; and decreased when only considering studies of patients who were in a stable drug regime before and during the trial, d=0.34 (95% CI, 0.01 - 0.67) [30].

A recent meta-analysis that includes studies up to December, 2017 [31] on rTMS treatment in schizophrenia, established that, for rTMS treatment, the mean weighted effect size compared to sham stimulation was 0.64 (0.32–0.96; k=22, total N=827) showing that noninvasive neurostimulation can improve negative symptoms in patients with schizophrenia. Moreover, this study suggested that protocols with high frequency stimulation containing more than 7500 stimuli per week at an intensity of>100% motor threshold, may be more effective than other protocols especially in younger patients with a shorter duration of illness.

Another meta-analysis [32] revealed that at a 10 Hz setting at least 3 consecutive weeks of treatment, treatment site DLPFC and a 110% motor threshold were found to be the best rTMS parameters for the treatment of negative symptoms, although the application of active 10-Hz rTMS to the left dorsolateral prefrontal cortex was well tolerated, but it was not superior compared with sham rTMS in improving negative symptoms in another recent study [33] on 175 patients with a high-degree illness severity.

Dougall et al. [34], however, conclude that there is insufficient evidence to support or refute the use of TMS to treat schizophrenia symptoms, and none to suggest any added benefits with TMS used as an adjunctive therapy to antipsychotic medication. The study included 41 studies with 1473 participants.

Other paradigms and preliminary studies

Up to this moment, the vast majority of studies with rTMS for this pathology have included in their protocol either LF-rTMS over temporoparietal cortex to treat AVH or HFrTMS to the left DLPFC for negative symptoms. In the search for novel target sites or protocols to improve outcomes, a preliminary study using HF-rTMS (20 Hz) guided by anatomical and fMRI has reported a significant reduction in global severity and frequency of AVH between baseline and day 12 post-treatment [25]. Moreover, according to its authors, some of these effects continued for up to six months [25].

On the other hand, a case-report revealed that HF-rTMS (5 - 7 Hz) over the cerebellar vermal may result in the worsening of AVH [35], contrary to the results of a series of eight cases in which the application of intermittent theta burst stimulation (iTBS) (short trains of 50 Hz with a rate of 5 Hz (theta rhythm)) over the same area that to be safe and well-tolerated, while offering a positive impact on mood and cognition [36].

It should be noted that the application of theta burst stimulation (TBS) is faster and appears to induce more lasting effects than those achieved by conventional rTMS. This paradigm is mainly inhibitory when applied continuously (cTBS) and excitatory when done so intermittently [37]. Regarding TBS and schizophrenia, three casereports revealed improvement of untreatable AVH after the application of cTBS over left temporoparietal cortex [38,39] and the same area bilaterally [40]. These findings set the basis for the development of a RCT that compared treatment with classical LF-rTMS (1 Hz) to cTBS over the left temporoparietal cortex, concluding that cTBS is safe, faster but does not have clinical advantages compared with the conventionally used 1-Hz TMS protocol in AVH [41].

Similarly, in contrast to the normal use of the left DLPFC to improve negative schizophrenia symptoms by means of HF-rTMS, Dablac-de- Lange et al., [42], used bilateral DLPFC in a study employing 10 Hz for 3 weeks, concluding that bilateral 10 Hz prefrontal rTMS reduced negative symptoms for up to 3 months after its application compared to the sham group.

To summarize, taking into account the evidence found, it could be concluded that LF-rTMS over left temporoparietal cortex may be an effective treatment for AVH but not for other positive symptoms. Furthermore, the duration of the effects of rTMS over AVH is short. This inconvenience, combined with a small treatment effect, may call into question its utility as a useful treatment for patients troubled with persistent symptoms. In terms of negative symptoms, in spite of the promising results of some studies, the potential of HF-rTMS for the treatment of negative symptoms is currently relatively unclear. Thus, further RCTs are needed to clarify the role of TMS in the treatment of schizophrenia.


The therapeutic effects demonstrated by TMS in depression have become the paradigm of the effectiveness of this therapy.

Pathophysiology of depression and mechanisms underlying the therapeutic effect of TMS

Depression is one of the most prevalent mood disorders in existence. It is estimated that in the U.S. around one out of every six subjects will suffer from any form of clinical depression throughout their lives, often closely related to other neurodegenerative processes such as Alzheimer´s disease (AD), Parkinson´s disease (PD), or Huntington´s disease (HD) among others. The core symptom of this disorder is to be in a low mood, although depression is always accompanied by other symptoms such as irritability, anhedonia, and disturbances in sleep, appetite, and cognitive functions. The diagnosis of a major depressive disorder (MDD), as well as other clinical forms of depression, is based on several diagnosis criteria perfectly defined in the Diagnostic and Statistical Manual of Mental Disorders (fourth edition; DSM - IV). However, its pathophysiological mechanisms have not yet been fully elucidated [43,44].

In this direction, experimental models have linked depression to oxidative stress and cell damage [45]. Supporting this hypothesis, treatment with proven antioxidant- effect substances such as 17β-estradiol, nicotine and melatonin have been demonstrated to reverse the oxidative changes and behavioral alterations induced by the models [45-47]. In addition, treatment with extremely low-electromagnetic field (EL-EMF) (60 Hz, 0.7 mT), a type of electromagnetic therapy similar to TMS, achieved similar effects to those induced by antioxidant substances [48] and even to those found in similar experimental models after the application of electroconvulsive therapy (ECT) [49,50].

From another point of view, a great deal of scientific evidence supports the role of alterations in brain-derived neurotrophic factor (BDNF)-mediated neuroplasticity, as well as the participation of proinflammatory cytokines as adjuvants in the pathogenesis of this complex disorder [43,44]. According to some authors, oxidative stress markers and BDNF might even become future depression biomarkers [51]. In this respect, the application of HF-rTMS (20 Hz) produces changes in the expression of BDNF and cholecystokinin in rat brain, data that are consistent with those found after administration of antidepressant drugs (mianserin, desimipramin or sertraline) and ECT [52], pointing to this route as being one of the bases for the therapeutic effect of TMS in mood disorders such as depression [53]. Similarly, after successful antidepressive treatment with HF-rTMS (15 Hz) over left prefrontal cortex, myo-Inositol, an alcohol involved in functions such as nerve guidance, cell membrane potential maintenance or serotonin activity modulation, increased significantly in left prefrontal cortex emphasising the importance of metabolic alterations in major depression [54]. Nevertheless, it is beyond question that the pathophysiology of depressive disorders is extremely complex and not exclusively a problem of oxidative damage and cell dysfunction.

Thus, depression appears to be associated with pathophysiological and structural brain abnormalities such as dysregulation of hypothalamo-pituitary-adrenal and hypothalamo-pituitary-thyroid axes, reduced hippocampal volumes and prefrontal cortex activity [44]. Genetic vulnerability and stress have also been proposed as being pathogenic elements in depression [44].

In this line, depressive patients who respond to TMS therapy (HF-rTMS 10 Hz over left prefrontal cortex) showed an elevation of serum levels of the thyroid-stimulating hormone (TSH) [55]. Similarly, a negative correlation between pre-treatment TSH levels and decrease (%) in the Hamilton Rating Scale for Depression (HAM-D) score has been reported using LFrTMS (1 Hz) over the right DLPFC [56].

There is also evidence that the hypothalamicpituitary- adrenal axis is modified by application of HF-rTMS (10 Hz) to the left DLPFC, significantly decreasing salivary cortisol concentrations immediately and 30 minutes after rTMS, regardless of its effect on mood [57]. Similar changes in this axis have been observed in both healthy subjects [58] and animals [59], and they could explain why rTMS normalizes the dexamethasone suppression test, a remission feature in depressive patients under treatment [60,61].

Finally, a well-defined disorder of neurotransmitters (mainly serotonin and norepinephrine, but also others) occurs in depression, the latter being the basis of current pharmacological treatment. Nowadays, the most commonly used drugs are the selective serotonin re-uptake inhibitors (SSRIs), although classic tricyclic antidepressants or serotoninnorepinephrine reuptake inhibitors (SNRIs) are presented as an alternative or even first line treatment in some cases. Nevertheless, despite the good outcomes of antidepressant drugs, there are a considerable number of patients who will not respond to therapy with these medicaments. For this subgroup, TMS treatment, due to its capacity to modulate some pathophysiological processes involved in the neurobiology of depression has been proven effective as a therapeutic alternative [62].

Medical evidence and clinical effectiveness of classic rTMS-protocols on depression

In October 2008, the U.S. FDA approved the first TMS devices (NeuroStar TMS Therapy© System, Neuronetics, Inc., Malvern, PA, US) which, to date, are only authorized for the treatment of patients with MDD that failed to respond to one appropriate pharmacological treatment. This landmark was possible after more than one decade of research. The first preliminary studies and series of cases published in this respect date from the mid-1990s [63-65]. In subsequent years, and up to the FDA´s approval, approximately a hundred clinical trials have been carried out, concluding from the vast majority of them, that TMS causes a therapeutic effect on patients with MDD.

Probably due to the fact of being an emerging technique whose stimulation parameters were not standardized, as well as the initial absence of RCTs, the first meta-analyses that assessed the efficacy of TMS therapy in MDD resulted in offering a very low level of evidence or were of a doubtful clinical significance [66-69]. However, to prove the hypothesis that the experience accumulated over the years in the use of TMS, as well as a better study design, had improved the outcomes of this therapy in MDD, in 2007, Gross et al. [70] compared a meta-analysis of five RCTs (274 patients) published just twelve months prior to their paper with the meta-analysis of Martin et al. [67] (thirteen RCTs, 324 patients) that represented “the earlier studies”. Their findings demonstrated that recent RCTs (five) using HF-rTMS showed greater antidepressant effects when compared with the earlier studies. The pooled effect size (standardized mean difference between pretreatment vs. post-treatment) from the random effects model was -0.76 (95% CI, -1.01 - -0.51) versus -0.35 (95% CI, -0.66 - -0.04), respectively [70]. Later studies, including one meta-analysis (29 RCTs, 1371 subjects with MDD) [71], corroborate the hypothesis of Gross et al. [70] pointing to HF-rTMS applied to the left DLPFC as a safe and effective therapeutic tool in both acute and maintenance treatment of patients with MDD [72-75]. Furthermore, according to some authors, HF-rTMS therapy to the left DLPFC may be at least as effective as a subset of commercially available antidepressant drug agents [76] and undoubtedly, accelerates and enhances the clinical response to antidepressants [77,78].

Regardless of the effect on mood demonstrated by this therapy, some authors have suggested that TMS, mainly HF-rTMS (20 Hz) over the left DLPFC, may have an impact on psychomotor symptoms accompanying those patients with MDD. However, the scant literature existing in this regard is contradictory, not allowing one to confirm or rule out this hypothesis until new RCTs are carried out focusing on this issue [79,80]. Regarding other symptoms, treatment of depressive patients with rTMS, both HFrTMS and LF-rTMS, not only does not worsen cognitive function [81] but, according to some works, results in a beneficial effect in working memory-executive function, objective memory or fine motor speed domains [82-86].

Regarding remission and relapse rates, the most recent long-term follow-up studies report that over 50% of the patients treated with HF-rTMS (10 Hz) over the left DLPFC remain in remission for three months post-treatment [87,88]. A similar trial carried out with adolescent patients is much more optimistic since it concludes that eight out of nine treated patients showed no evidence of deterioration in symptoms of depression or cognitive functioning at a 3-year follow-up [89], although the level of evidence of this trial is low. In this line, in order to maintain long-term remissions and avoid early relapses, clustered-maintenance rTMS which involves monthly maintenance sessions of five HF-rTMS treatments over a two day period, may have the potential to substantially delay the occurrence of relapse following a successful course of rTMS treatment [90]. Two years earlier, a study using similar methodology had already pointed to this possibility [88]. Similarly, in patients with partial remission after drug treatment, ten sessions of HF-rTMS (10 Hz) over the left DLPFC may lead to achieve rates of complete remission (HAM-D < 8) of up to 78% at 12 months [91]. In this respect, a RCT is currently running to evaluate the efficacy of HF-rTMS (10 Hz) over the left DLPFC in the prevention of relapse of depression [92].

Despite the above mentioned studies, rTMS remains as a second-line therapy in MDD. Data from meta-analyses report relatively low response and remission rates (25-29.3% and 17–18.6%, respectively) [71-93], with a short duration of therapeutic effects in many cases (weeks to months), and a warning about the relative lack of systematic follow-up studies. For these reasons, further RTCs are needed before HF-rTMS can be considered as a first-line monotherapy treatment for MDD [93].

To conclude this section, it should be highlighted that TMS therapy may also be a valid method to treat the depressive disorder associated with other neurodegenerative and psychiatric conditions. Such is the case of Parkinson disease (PD) in which, in addition to motor and cognitive improvements, HFrTMS (5 Hz) over the left DLPFC has exerted an antidepressant effect [94]. According to some authors, this intervention might be as effective as fluoxetine, a SSRI [95]. Similarly, in postpartum depression, the application of HF-rTMS (5 Hz or 10 Hz) may become a safe and effective alternative to pharmacological treatment, besides producing marginal gains in social and cognitive function [96,97]. Equally, LF-rTMS (1 Hz) over right DLPFC seems to be effective in the treatment of panic disorder with comorbid major depression [98], and HF-rTMS (10 Hz) over the right DLPFC may improve depression secondary to obsessive-compulsive disorder [99]. Moreover, in a RCT of twenty-two women with MDD in the second or third trimester of pregnancy that received 20 sessions of TMS to the right dorsolateral prefrontal cortex at 1 Hz as a single train of 900 pulses per session at 100% motor threshold, demonstrated that TMS was effective in reducing depressive symptoms in this sample of pregnant women. However, there is a possibility that TMS could be associated with late preterm birth, although a larger sample size would be needed to detect it [100]. Finally, the effect of rTMS therapy on mood has also been observed in patients with fibromyalgia [101].

Predictive factors of responders to TMS treatment

The possibility of foreseeing which patients will respond to a specific treatment is a basic endpoint in many medical trials. In addition to the potential therapeutic benefit for a certain subgroups of patients, it improves the costeffectiveness ratio of the therapy. In the work concerning us, several studies have been carried out with interesting results to answer this question (Table 1).

- - Treatment refractoriness
- Older patients
HF-rTMS Left DLPFC 2 a [102]
Younger patients (< 45 years) - LF-rTMS (1 Hz) Right DLPFC 2 b [103]
- Low score of treatment resistance.
- Short duration of episode.
- High level of sleep disturbances.
- HF-rTMS (20 Hz) Left DLPFC 2 b [104]
Duration of depressive episode (< 4 years) - HF-rTMS (10 Hz) Left DLPFC 2 b [107]
High extraversion levels - HF-rTMS (10 Hz) Left DLPFC 2 c [109]
- Smaller deactivations in the anterior cingulate, the left medial orbitofrontal and the right middle frontal cortices.
- Larger activations in the left ventral-caudal putamen.
- HF-rTMS (15 Hz) Left DLPFC 2 b [111]
Lower DLPFC/VMPFC CBF ratio - HF-rTMS (10 Hz) Left DLPFC 2 c [134]
Increased CBF in the ventromedial prefrontal cortex - LF-rTMS (1 Hz) Right DLPFC 2 c [114]

Table 1: Positive and negative predictors of response to TMS-therapy in patients with MDD.

In 2006, Fregni et al. pooled data from six separate clinical trials (195 patients) concluding that age and treatment refractoriness were significant negative predictors of depression improvement [102]. Later, other studies have corroborated the hypothesis that young patients show better antidepressant response to LF-rTMS (1 Hz) over the right DLPFC than older ones [103]. In the same line, Brakemeier et al., in a study with 70 depressive patients, after analyzing various biographical, clinical, and psychopathological parameters, concluded that a high level of sleep disturbance, a low score of treatment resistance and a short duration of depressive episode were significant positive predictors for treatment response to HF-rTMS (20 Hz) over the left DLPFC [104]. A year later, this same research group, using these data combined with Fregni’s [102], carried out a joint analysis of the two studies, whose unique relevant conclusion was that a high level of therapy resistance is associated with poor outcome, suggesting that future predictor studies should focus on large, homogeneous samples of TMS multicentre trials and include neurobiological variables [105]. Finally, a study in 117 patients, with mood or anxiety disorders, have demonstrated that 10 sessions of HF-rTMS (10 Hz) over the left DLPFC were more effective in adolescent patients than in adults [106].

In relation to the evolution of the depressive episode as a predictor of response to TMS therapy, a trial revealed that a shorter duration of a depressive episode may predict response to HF-rTMS (10 Hz) over the left DLPFC since patients with a depressive episode duration of less than 4 years had a mean HAM-D decrease of 52% compared to 6% in those with an episode duration longer than 10 years [107]. Another interesting approach to this problem proposes to predict clinical response to rTMS by baseline lateral visual-field stimulation [108], or even by determining pre-treatment levels of extraversion and neuroticism [109].

The introduction of RMI to this type of studies has reported promising outcomes. In 2012, Furtado et al. [110] published a prospective study that, using daily treatment (five days a week) with HF-rTMS (10 Hz) over the left DLPFC for six weeks, with MRI and neuropsychological assessment, attempted to demonstrate whether the volume of the hippocampus and the amygdala, as well as the neurocognitive profile, could be used as predictors of response to treatment. In this regard, no differences were found in those parameters between responders and non-responders. Only a shorter pre-treatment in the left hippocampus volume showed a trend towards predicting eventual subjective improvement in depressive symptomatology [110]. Also making use of the fMRI, an RCT conducted with twenty-one depressive patients, who were randomized to sham rTMS or HFrTMS (15 Hz) over the left DLPFC, concluded that, in the active rTMS group, larger HAM-D reductions were significantly correlated with smaller deactivations during pre-treatment fMRI assessment in the anterior cingulate, the left medial orbitofrontal and the right middle frontal cortices, in addition to greater activations in the left ventral-caudal putamen [111]. Similarly, another study using MRI and positron emission tomography (PET) reported that both preserved left lateral orbitofrontal cortex volume and amygdala metabolism might precondition response to HF-rTMS (10 Hz) over prefrontal cortex in MDD [112].

In the same direction, it seems that both some patterns of cerebral perfusion and certain patterns of EEG may be linked to a more pronounced antidepressant response to rTMS therapy. Indeed, patients with a lower cerebral blood flow (CBF) ratio of the DLPFC to the ventromedial prefrontal cortex may show a better response to HF-rTMS (10 Hz) over the left DLPFC [113]. Equally, depressed patients with increased CBF in the ventromedial prefrontal cortex and decreased CBF in the orbitofrontal cortex and the subgenual cingulate cortex may exhibit a better response to right prefrontal LF-rTMS (1 Hz) [114,115]. Moreover, a recent study showed that single pulse TMS to the left DLPFC using a unique TMS-fMRI set-up, triggered activity in the subgenual anterior cingulate cortex in four out of nine participants [116]. Nevertheless, it has been demonstrated that the changes in CBF after rTMS therapy may present a significant individual variability, making it difficult to analyze the results based on this parameter [117]. A later study showed that changes in frontal cerebral blood volume, measured as frontal hemoglobin concentration during TMS, are correlated with clinical outcomes of treatment [118].

Finally, some pilot studies suggest that certain EEG patterns could be useful as predictors, making it feasible to predict rTMS treatment efficacy of either treatment modality (HF-rTMS and LF-rTMS) with a specificity of 83% and a sensitivity of 78%, for a combined accuracy of 80% using a statistical prediction model based on a mixture of factor analyses [119], even in the first week of rTMS [120]. A fact of note is that increased low-theta power in the subgenual anterior cyngulate cortex could also predict response to HF-rTMS (10 Hz) over left DLPFC in patients with vascular depression [121] and MDD [122]. Similarly, pretreatment alpha band power on parieto-temporal regions might be a predictor for response to HF-rTMS (10 Hz) over the left DLPFC [123]; however, in this study the sample was a small one and the patients heterogeneous, so this result should be treated with caution. A later study suggested that 10 Hz motor cortex (MC) rTMS was predictive of the antidepressant effect of 10 Hz DLPFC rTMS [124].

Low frequency rTMS versus High frequency rTMS

While the majority of studies that have pointed to TMS therapy as being effective in the treatment of depression have been carried out using HFrTMS over the left DLPFC, in recent years, much evidence showing that the effects induced by LF-rTMS (1 Hz) over the right DLPFC can be comparable has been published. This effect of LF-rTMS has been known since more than ten years ago when preliminary studies reported antidepressant outcomes from this protocol [22,125,126]. From then until now, several works have been published corroborating the antidepressant effect of LF-rTMS (mainly 1 Hz) to the right DLPFC in patients with depression [82,127-130]; this effect could be comparable to antidepressant drugs like venlafaxine [131].

Two recent meta-analyses collecting data from eight RCTs each one, (263 patients) [132] and (249 patients) [133], show major evidence for the beneficial effect of this form of rTMS in the treatment of MDD. These studies conclude that LF-rTMS (1 Hz) to the right DLPFC provides clinically meaningful benefits that are comparable to those of standard antidepressants and HF-rTMS [118] with fewer side effects [133].

Regardless of whether the final antidepressant effects are equal, those of both types of stimulation (LF-rTMS and HF-rTMS) on activity and brain metabolism, as well as on regional CBF, are completely different [134], besides their individual variability [117]. Globally, the majority of studies agree that HFrTMS induces a more extensive increase in brain activity and regional CBF, while LF-rTMS shows a slight decline in brain activity and regional CBF in much localized areas. These facts point to the different neurophysiological, and possibly neuropsychiatric, consequences of changing the rTMS frequency [115,135,136].

Despite these differences with respect to changes in brain metabolism and CBF, there is no doubt that both therapies exert a benefit on mood. Various studies comparing the effect of both protocols concluded that they do not differ as regards their antidepressant power [128,137-138]. Moreover, when only responder-totherapy patients were evaluated, equivalent brain single photon emission computed tomography (SPECT) perfusion changes underlying therapeutic efficiency of both protocols are found [140].

In conclusion, keeping in mind that there is no difference between the effectiveness of both rTMS protocols and that LF-rTMS sessions are shorter, possibly better tolerated and with fewer side effects, LF-rTMS to the right DLPFC is emerging as an even superior treatment alternative to HF-rTMS over the left DLPFC in MDD, particularly in bipolar patients with a higher anxiety degree [130].

New trends and strategies in TMS and depression

Once TMS therapy has shown itself to be effective and safe [1], new trends in the use of this technique have focused on discovering protocols and types of stimulation with greater effects and an equal safety. Therefore, changes in the frequency and the type of pulse, as well as structural modifications of TMS devices are being tested with that aim.

From the point of view of TMS devices, the introduction of a double-cone coil with large angled windings could allow direct stimulation of deeper areas such as the anterior cingulate cortex, thus increasing the likelihood of treatment success in some contexts [141]. 2-coil rTMS device over the left DLPFC prefrontal cortex and dorsomedial prefrontal cortex could possess episodic memory-enhancing capabilities [142]. With the same aim, the use of deep-TMS over the prefrontal cortex using H-coil improved both apathy and depression similarly, although it was unable to induce remission in patients with higher scores in apathy-related items of HAM-D. In this regard, it is suggested that this phenomenon should be investigated in order to predict the effectiveness of deep-TMS in MDD [143]. Other studies have also reported that deep-TMS may be beneficial in MDD, augmenting antidepressant medications and/or improving depressive symptoms [144,145].

Aside from the shape of the coil, improvements in its positioning might improve the antidepressant outcome of rTMS [146]. Thus, the introduction of neuronavigation equipment could ensure a better placement of the coil, eliminating the individual variability and improving the results obtained with this therapy [147-151]. The use of background EEG activity to determine stimulus timing as a means of improving rTMS efficacy has also proved useful [152].

From a different point of view, modifications of current standard protocols, as well as the use of other types of TMS, could open up a path towards the improvement of the effectiveness of TMS. In this regard, it has been suggested that ultra-HF-rTMS (30 Hz) over the left DLPFC might be a more effective protocol although, so far, this modality has only been seen to be a safe alternative that induces an improvement in processing speed performance, but not as a useful antidepressant therapy [153].

On the other hand, one of the disadvantages of rTMS treatment is the discomfort caused by current schemes based on daily sessions during two or four weeks, which often deters adherence to treatment. To solve this problem, accelerated TMS protocols, with the complete treatment administered over a few days, would have significant advantages in terms of access and patient acceptance. In this sense, preliminary studies suggest that accelerated TMS might afford an excellent safety profile with an efficacy comparable to that achieved in daily rTMS in other trials [154]. In the same way, another form of patterned-TMS protocol, TBS, has also demonstrated its safety, tolerability and preliminary evidence for antidepressant effectiveness when applied to the left or right DLPFC at different stimulation parameters [155].

Other alternatives to existing standard protocols are either combined sequential use of LFrTMS and HF-rTMS, or the application of one of those protocols bilaterally. In this latter regard, some RCTs support the hypothesis that sequential bilateral rTMS (LF-rTMS then HF-rTMS or vice versa) is effective and safe [156,157], but not more effective than unilateral HF left-sided rTMS [158-160], or unilateral LF right-sided rTMS [160,161]. Thus, according to the conclusions of a meta-analysis conducted by Berlim et al. [162], who obtained data from seven RCTs (279 subjects), bilateral rTMS is a promising treatment for major depression as it provides clinically meaningful benefits that are comparable with those of standard antidepressants and unilateral rTMS. A metaanalysis with data obtained from 25 studies consisting of 1288 individuals with MDD, demonstrated that electroconvulsive therapy was the most efficacious, but least tolerated, treatment, LF-rTMS was the best tolerated treatment for MDD and bilateral rTMS appears to present the most favorable balance between efficacy and acceptability [163]. However, electroconvulsive therapy appears to result in a higher percentage of side effects compared with TMS treatment [164].

Another new scheme using frequency-modulated priming stimulation seems to increase the effect of rTMS therapy. A study carried out with forty patients with moderate-to-severe depression concluded that pre-stimulation with frequencymodulated priming stimulation in the theta range (4-8 Hz; 400 pulses) has a greater antidepressant effect than low-frequency stimulation alone [165]. Other previous trials using similar protocols corroborate these results [166,167]. Augmentative rTMS to the left dorsolateral prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration), 3000 pulses per session using a figure-eight coil, with a minimum of 20 sessions during four weeks, was more effective on depression and anxiety symptoms than standard therapy (psychopharmacotherapy and psychotherapy) in MDD [168].

As a novel strategy in the use of TMS in MDD, some works have pointed to the usefulness of combining rTMS therapy and antidepressant drugs from the very first moment, just after the diagnosis of MDD, since this strategy might accelerate the antidepressant response in firstepisode onsets. This conclusion was reached in a study conducted with sixty young depressive patients who started treatment from the beginning with citalopram and sham or rTMS therapy during two weeks [169]; or a recent study with 281 depressed patients who had achieved stable full or partial remission on a 6-month antidepressant (ADP) run-in treatment and were randomly assigned to an rTMS (n=91), ADP (n=108), or combined (rTMS + ADP, n=82) treatment group for 12 months in 5-10 sessions over a 3-5-day period/monthly. This study concluded that TMS, whether as a mono- or additional therapy, is superior to antidepressants in preventing depressive relapse/ recurrence, particularly in first-episode depressed patients [170].

Another study in 196 patients combining rTMS and psychotherapy, based on principles of cognitive behavioral therapy, during 10 sessions, resulted in a 66% response and a 56% remission rate at the end of the treatment, with 60% sustained remission at follow-up [160]. Russo et al [171] concluded that Incorporation of a modified version of Behavioral Activation therapy during transcranial magnetic stimulation is feasible, well tolerated, and holds a potential for augmenting the efficacy of TMS treatment for patients with treatment-resistant depression.

In conclusion, despite all this novel evidence, new RCTs are needed to compare the safety and antidepressant effect among these new devices, protocols and strategies, and the classic protocols (HF-rTMS 10 - 20 Hz over left DLPFC or LFrTMS 1 Hz over right DLPFC) prior to their introduction in daily clinical practice.

Other Psychiatric Disorders

As a consequence of the good therapeutic results obtained through the use of different TMSprotocols in depression and schizophrenia, many other studies have attempted to demonstrate a possible beneficial effect of this technique in other psychiatric disorders.

On the opposite side of depression is mania, a disorder included in some forms of bipolar disorder for which treatment with TMS is also in study. The first reference on this subject was published in 1998 [172]. That trial, comparing the use of HF-rTMS (20 Hz) on the right and left DLPFC, concluded that a more significant improvement was observed in patients treated with right than with left HF-rTMS. This finding led to proposing that the therapeutic effect of TMS in mania showed opposite laterality to that found in depression [172].

More recent studies assessing the usefulness of TMS in mania are contradictory. Thus, a trial using HF-rTMS (20 Hz) over the right DLPFC did not demonstrate that real stimulation was more effective than sham stimulation [173]. However, its authors report that the patients included in the study had a major psychotic component that could have interfered in the outcomes [173], since other similar studies support the positive effect of HF-rTMS over right DLPFC in mania [174-176]. Despite the latter, current evidence does not recommend a therapeutic use of TMS in mania, further investigations into this subject still being necessary in order to elucidate a possible role of this treatment in mania.

Related to mania, a specific problem in the use of TMS in psychiatric patients that has concerned researchers is the possibility that it induces treatment-emergent mania/hypomania (TEM). A meta-analysis focused on this eventuality revealed that rTMS treatment carries a slight risk of TEM that is not statistically higher than that associated with sham treatment [177]. Moreover, in those cases in which it appears, decrease or discontinuation of antidepressant and/or rTMS treatment and/or use of anti-manic medication can treat this complication effectively. Reducing the frequency of sessions from two per day to one could also reduce the likelihood of TEM recurrence [177].

Another disorder candidate for treatment with TMS is posttraumatic stress disorder (PTSD), a severe anxiety condition that can develops after exposure to any event that results in producing psychological trauma. Preliminary studies on the subject showed improvement of the core symptoms of PTSD (avoidance, anxiety and somatization) with a single session of LF-rTMS (0.3 Hz) over the motor cortex, although the effect was short and transient [178]. One of the latest RCTs (20 patients) conducted in this regard concluded that ten sessions of LF-rTMS (1 Hz) over the right DLPFC resulted in statistically and clinically significant improvements in core PTSD and depressive symptoms, compared with sham treatments, effects that lasted up to two months post-treatment [179]. Using the same stimulation pattern, similar outcomes were found by Nam et al. [180].

In the same line, studies with HF-rTMS (10 Hz) over the right DLPFC have shown a greater therapeutic effect on core symptoms (re-experiencing and avoidance), and on the relief of anxiety, than LF-rTMS (1 Hz)[181]. Furthermore, another study that evaluated the effect of HF-rTMS (20 Hz) on both right and left DLPFC in patients with PTSD allowed one to elucidate that this therapy applied to the right side may be more beneficial for anxiety control and core symptoms, while it showed a significantly greater effect on mood when applied on the left [182]. Other authors have also reported this latter effect [183]. Based on this background, some authors have theorized that daily applications of HF-rTMS in PTSD patients may reduce access to the set of autobiographical stored events that, if re-experienced, may cause the overt PTSD symptoms [184]. However, this theory has not been proven yet.

Regarding another anxiety disorder, obsessivecompulsive disorder (OCD), the available literature is as scant as it is interesting. In 2003, Martin et al. [185] carried out a Cochrane review analyzing the possible effect of TMS on patients with OCD. Three RCTs were included in the analysis but only two contained data in a suitable form for quantitative analysis which, finally, was not possible. Therefore, no conclusion on the efficacy of TMS in the treatment of OCD was drawn [185]. On the contrary, in 2013, a meta-analysis conducted by Berlim et al. [186] including data from ten RCTs (282 subjects) has revealed more promising outcomes. Those authors concluded that, following a mean of 14 sessions, rTMS seems to be effective in treating OCD-related symptoms mainly when LF-rTMS and protocols targeting non-DLPFC areas (orbitofrontal cortex or supplementary motor area (SMA)) are applied. HF-rTMS placed over the DLPFC does not seem to be more effective than sham rTMS [186]. In addition, in their opinion, rTMS could be as effective as other second- or third-line pharmacological strategies for OCD with fewer metabolic adverse effects. TMS could be used to facilitate the response to medication for which dose increases for the patient are not possible [187]. TMS DLPFC during the viewing of symptom-provoking stimuli may facilitate the response to subsequent cognitive behavioral therapy [188].

Future studies will help to elucidate the role that rTMS could play in the treatment of PTSD and OCD. New RCTs will be necessary to clarify the most adequate and effective protocol for these patients, as well as the impact of new neuromodulation devices.

Finally, almost anecdotally, TMS has been used and might open up new fields of research in children with Tourette’s syndrome [189,190] and psychogenic movement disorders [191]. Furthermore, there are an increasing number of works suggesting that TMS may have a role in the treatment for dependency on drugs such as alcohol [192], tobacco [193-196] or opioids [197]; showing once more, the therapeutic potential of an emerging technique in constant evolution.


In summary, TMS is presented as a novel, powerful, non-invasive therapeutic strategy in psychiatric disorders. This therapy appears to modulate several biochemical processes that might be involved in its therapeutic effects. Regarding the clinical evidence of the use of TMS in psychiatry (Table 2) we can conclude that:

Reduction of AVH Schizophrenia cTBS Left temporoparietal cortex 2 b [41]
(1 Hz)
Left temporoparietal cortex 1 a [24]
Guided-fRMI HF-rTMS
(20 Hz)
Left superior temporal sulcus 4 [25]
Decrease hypofrontality Schizophrenia HF-rTMS
(10 Hz)
Left DLPCF 1b [19]
Improvement on positive and psychotic symptoms Schizophrenia Alpha-EEG-guided rTMS Bilateral frontal or parietal cortex 2 b [18]
Improvement on negative symptoms Schizophrenia HF-rTMS
(10 Hz)
Left DLPFC 1 a [30]
Bilateral prefrontal 1b [42]
Reduction of tobacco craving Schizophrenia HF-rTMS
(20 Hz)
Bilateral DLPFC 2 b [195]
Reduction of cigarette consumption Schizophrenia HF-rTMS
(10 Hz)
Left DLPFC 2 b [196]
Antidepressant effect MDD HF-rTMS
(10 – 20 Hz)
Left DLPFC 1 a [77]
(1 Hz)
Right DLPFC 1 a [132]
Deep TMS Prefrontal cortex 4 [145]
Sequential bilateral rTMS Left and right DLPFC 1 b [157]
rTMS Bilateral DLPFC 1 a [162]
(5 Hz)
Left DLPFC 2 b [94]
Postpartum depression HF-rTMS
(5 Hz)
Left DLPFC 2 b [97]
Panic Disorder LF-rTMS
(1 Hz)
Right DLPFC 4 [98]
(10 Hz)
Right DLPFC 2 b [99]
Fibromyalgia LF-rTMS
(1 Hz)
Right DLPFC 2 b [101]
Amelioration of psychomotor symptoms MDD HF-rTMS
(10 Hz)
Left DLPFC 4 [80]
Positive effect on cognitive function MDD LF-rTMS
(1 Hz)
Right DLPFC 4 [82]
(10 Hz)
Left DLPFC 4 [86]
Schizophrenia iTBS Cerebellar vermal 4 [36]
Amelioration of mania symptoms Bipolar disorder HF-rTMS
(20 Hz)
Right DLPFC 2 b [176]
Improvement of core symptoms PTSD HF-rTMS
(20 Hz)
Right DLPFC 2 b [182]
(1 Hz)
Right DLPFC 2 b [179]
Anti-obsessive (Improvement YBOCS) OCD rTMS
(LF-rTMS 1Hz)
SMA or orbitofrontal cortex 1 a [186]

Table 2: Clinical effects of TMS on psychiatric disorders.

Depression represents the paradigm of the therapeutic effectiveness of TMS in psychiatric diseases. In addition, a great deal of evidence shows beneficial effects of this therapy on AVH of schizophrenia, as well as on the symptomatology of other psychiatric disorders such as PTSD or OCD.

In spite of the excellent outcomes reaped by TMS as a therapy so far, this should be still considered as an emerging technique and, therefore, new RCTs are needed to clarify its role in the treatment of psychiatric disorders and how new protocols and technologies might improve the results obtained by this novel therapy.

Conflict of Interest

The authors report no conflict of interest.


AD:Alzheimer´s disease; AVH: Auditory verbal hallucinations; BDNF: Brain-derived neurotrophic factor; CBF: Cerebral blood flow; cTBS: Continuous theta burst stimulation; DLPFC: Dorsolateral prefrontal cortex; ECT: Electroconvulsive therapy; EEG: Electroencephalography; EL-EMF: Extremely low-electromagnetic field; FDA: U. S. Food and Drug Administration; HAM-D: Hamilton Rating Scale for Depression; HD: Huntington´s disease; HF-rTMS: High frequency repetitive transcranial magnetic stimulation; iTBS: Intermittent theta burst stimulation; LF-rTMS: Low Frequency repetitive transcranial magnetic stimulation; MDD: Major depressive disorder; MRI: Magnetic Resonance Imaging; OCD: Obsessive-compulsive disorder PD: Parkinson´s disease; PET: Positron emission tomography; PTSD: Posttraumatic stress disorder; RCT:Randomized controlled trial; fRMI: Functional magnetic resonance imaging; SMA: Supplementary motor area; SNRIs: Serotonin– norepinephrine reuptake inhibitors; SPECT: Single photon emission computed tomography; SSRIs: Selective serotonin re-uptake inhibitors; TBS: Theta burst stimulation; TEM: Treatmentemergent mania/hypomania; TMS: Transcranial magnetic stimulation; rTMS: Repetitive transcranial magnetic stimulation.


Copyright © 2024 Neuropsychiatry Journal (London). All Rights Reserved.

antalya escort

izmir rus escort

bursa escort bayan

antalya escort bayanlar

izmir escort

porno indir

porno izle

beşiktaş escort

eskişehir escort

burdur escort

bartın escort


türk takipçi satın al

izmir escort

bursa escort

türk porno

escort bayan

yabanci porno

takipçi satın al

takipçi satın al

instagram takipçi satın al

instagram beğeni satın al

instagram takipçi satın al

takipçi satın alma


panel smm

takipçi satın al instagram

smm panel

ataköy escort

izmit escort